Literature DB >> 32616516

Obesity-Induced Increase in Cystatin C Alleviates Tissue Inflammation.

Mara A Dedual1,2,3, Stephan Wueest1,2, Tenagne D Challa1,2, Fabrizio C Lucchini1,2, Tim R J Aeppli1,2, Marcela Borsigova1,2, Andrea A Mauracher2,4, Stefano Vavassori2,4, Jana Pachlopnik Schmid2,4, Matthias Blüher5, Daniel Konrad6,2,3.   

Abstract

We recently demonstrated that removal of one kidney (uninephrectomy [UniNx]) in mice reduced high-fat diet (HFD)-induced adipose tissue inflammation, thereby improving adipose tissue and hepatic insulin sensitivity. Of note, circulating cystatin C (CysC) levels were increased in UniNx compared with sham-operated mice. Importantly, CysC may have anti-inflammatory properties, and circulating CysC levels were reported to positively correlate with obesity in humans and as shown here in HFD-fed mice. However, the causal relationship of such observation remains unclear. HFD feeding of CysC-deficient (CysC knockout [KO]) mice worsened obesity-associated adipose tissue inflammation and dysfunction, as assessed by proinflammatory macrophage accumulation. In addition, mRNA expression of proinflammatory mediators was increased, whereas markers of adipocyte differentiation were decreased. Similar to findings in adipose tissue, expression of proinflammatory cytokines was increased in liver and skeletal muscle of CysC KO mice. In line, HFD-induced hepatic insulin resistance and impairment of glucose tolerance were further aggravated in KO mice. Consistently, chow-fed CysC KO mice were more susceptible to lipopolysaccharide-induced adipose tissue inflammation. In people with obesity, circulating CysC levels correlated negatively with adipose tissue Hif1α as well as IL6 mRNA expression. Moreover, healthy (i.e., insulin-sensitive) subjects with obesity had significantly higher mRNA expression of CysC in white adipose tissue. In conclusion, CysC is upregulated under obesity conditions and thereby counteracts inflammation of peripheral insulin-sensitive tissues and, thus, obesity-associated deterioration of glucose metabolism.
© 2020 by the American Diabetes Association.

Entities:  

Year:  2020        PMID: 32616516     DOI: 10.2337/db19-1206

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  Prognostic Value of Pretreatment Serum Cystatin C Level in Nasopharyngeal Carcinoma Patients in the Intensity-modulated Radiotherapy Era.

Authors:  Xi-Rong Tan; Sheng-Yan Huang; Sha Gong; Yang Chen; Xiao-Jing Yang; Qing-Mei He; Shi-Wei He; Na Liu; Ying-Qing Li
Journal:  Onco Targets Ther       Date:  2021-01-06       Impact factor: 4.147

2.  Cre/CysC ratio may predict muscle composition and is associated with glucose disposal ability and macrovascular disease in patients with type 2 diabetes.

Authors:  Qing Yang; Mei Zhang; Peng Sun; Yanying Li; Huichao Xu; Kejun Wang; Hongshan Shen; Bo Ban; Fupeng Liu
Journal:  BMJ Open Diabetes Res Care       Date:  2021-11

Review 3.  Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease.

Authors:  Chan-Young Jung; Tae-Hyun Yoo
Journal:  Diabetes Metab J       Date:  2022-03-24       Impact factor: 5.376

4.  Serum Cystatin C Levels Are Associated With Obesity in Adolescents Aged 14-17 Years.

Authors:  Ying-Xiang Huo; Wei Wei; Yang Liu; Ya-Nan Ma; Jun-Min Tao; Ning-Ning Wang; Xiao-Feng Li; Xin Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-04       Impact factor: 5.555

5.  Creatinine-based GFR-estimating equations in children with overweight and obesity.

Authors:  Mark J C M van Dam; Hans Pottel; Anita C E Vreugdenhil
Journal:  Pediatr Nephrol       Date:  2022-02-24       Impact factor: 3.651

Review 6.  Assessment of kidney function: clinical indications for measured GFR.

Authors:  Natalie Ebert; Sebastjan Bevc; Arend Bökenkamp; Francois Gaillard; Mads Hornum; Kitty J Jager; Christophe Mariat; Bjørn Odvar Eriksen; Runolfur Palsson; Andrew D Rule; Marco van Londen; Christine White; Elke Schaeffner
Journal:  Clin Kidney J       Date:  2021-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.